Canada’s public health plans and Danish drugmaker Novo Nordisk NVO-N have broken off talks to cover the blockbuster weight-loss drug Wegovy.

The pan-Canadian Pharmaceutical Alliance (pCPA), a body that represents all federal and provincial drug plans, said Monday that it had concluded negotiations with Novo Nordisk without a deal after two months because the manufacturer had declined to negotiate Wegovy’s price.

Wegovy is a drug prescribed for weight loss that contains the same active ingredient – semaglutide – as Ozempic, which is prescribed for patients with type 2 diabetes.

Ozempic is by far the best-selling drug in Canada, earning $2.2-billion at retail pharmacies for the first nine months of 2025, according to aggregated prescription data collected by IQVIA Canada. Wegovy is No

See Full Page